VAX-31 is the Broadest Spectrum Pneumococcal Conjugate Vaccine in the Clinic Today

 Vaxcyte, Inc. today announced financial results for the second quarter ended June 30, 2024, and provided a business update.

“We continue to make significant strides toward building the potentially best-in-class pneumococcal conjugate vaccine (PCV) franchise and expect to announce the VAX-31 adult Phase 1/2 study topline safety, tolerability and immunogenicity data in September,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte, in a press release on August 6, 2024.

“Our clinical program assessing VAX-31, the broadest-spectrum PCV in the clinic today, will provide significant insights into the full potential of this vaccine candidate across the adult population."

"Following the VAX-31 adult data readout, we plan to advance either VAX-24 or VAX-31 into Phase 3 clinical development in adults.”

Mr. Pickering continued, “Additionally, we look forward to delivering the topline data from the primary immunization series of the VAX-24 infant Phase 2 study by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025."

"We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market today.”

The Company also confirmed cash, cash equivalents, and investments were $1,851.9 million as of June 30, 2024, compared to $1,242.9 million as of December 31, 2023.